Palisade Capital Managementnj buys $21,782,416 stake in Repligen Corporation (RGEN)

Repligen Corporation (RGEN) : Palisade Capital Managementnj scooped up 45,972 additional shares in Repligen Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 2, 2016. The investment management firm now holds a total of 720,318 shares of Repligen Corporation which is valued at $21,782,416.Repligen Corporation makes up approximately 0.92% of Palisade Capital Managementnj’s portfolio.

Other Hedge Funds, Including , Quantbot Technologies Lp added RGEN to its portfolio by purchasing 361 company shares during the most recent quarter which is valued at $10,917.California State Teachers Retirement System boosted its stake in RGEN in the latest quarter, The investment management firm added 1,201 additional shares and now holds a total of 70,804 shares of Repligen Corporation which is valued at $2,141,113.Boston Advisors boosted its stake in RGEN in the latest quarter, The investment management firm added 3,540 additional shares and now holds a total of 13,755 shares of Repligen Corporation which is valued at $389,404. Repligen Corporation makes up approx 0.01% of Boston Advisors’s portfolio. Summit Creek Advisors added RGEN to its portfolio by purchasing 111,221 company shares during the most recent quarter which is valued at $3,058,578. Repligen Corporation makes up approx 0.50% of Summit Creek Advisors’s portfolio. Cutler Group Lp added RGEN to its portfolio by purchasing 1,401 company shares during the most recent quarter which is valued at $37,211.

Repligen Corporation closed down -0.07 points or -0.23% at $30 with 2,47,731 shares getting traded on Monday. Post opening the session at $30.03, the shares hit an intraday low of $28.95 and an intraday high of $30.315 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Repligen Corporation reported $0.16 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $0.13. The company had revenue of $29.20 million for the quarter, compared to analysts expectations of $24.85 million. The company’s revenue was up 35.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.11 EPS.

Repligen Corporation (Repligen) is a life sciences company. The Company develops manufactures and markets bioprocessing products for life sciences and biopharmaceutical companies across the world. The Company is a manufacturer of both native and recombinant forms of Protein A critical reagents used in biomanufacturing to purify monoclonal antibodies which is a type of biologic drug. It also supplies several growth factor products and cell filtration products used to increase cell culture productivity during the bioproduction process. It has developed a series of OPUS chromatography columns for use in clinical-scale manufacturing. It manufactures and sells Protein A and growth factors to life sciences companies under supply agreements and sells chromatography columns as well as media and quality test kits and the Company’s Alternating Tangential Flow (ATF) products directly to biopharmaceutical companies or contract manufacturing organizations or through distributors.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *